Latest Financials News

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Fluence Corporation Limited reported a net cash outflow of US$3.03 million for the December 2024 quarter, maintaining liquidity with nearly US$9 million in cash and expanded credit facilities.

Dragon Mountain Gold Limited reports promising drilling results at its Avalon Project and prepares for further exploration at Cawse, supported by a successful $670,000 capital raise and strategic board appointment.

Gas2Grid navigates regulatory headwinds in Australia by pursuing new petroleum ventures in the Philippines while contesting a significant legal claim in France. The company’s ASX suspension persists as it seeks to restore compliance through fresh contracts.

Beonic's Q2 FY2025 results reveal steady recurring revenue growth and a significant gross margin improvement, underpinning its path to cashflow breakeven. Strategic contract wins and leadership appointments position the company for accelerated IoT adoption.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Advance Metals Limited has significantly expanded its portfolio with binding agreements to acquire high-grade silver and gold projects in Mexico and Australia, setting the stage for an active 2025 exploration campaign.

Elixir Energy wraps up Daydream-2 well operations and prepares for next appraisal in a strengthening gas market, while progressing farmout talks for Australian and Mongolian assets.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.

Lycaon Resources completes its first drilling program at the Stansmore Nb-REE target, revealing modest mineralization, while reinforcing its leadership with key board appointments and planned capital injections.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.